Insulin resistance is the inability to respond to insulin and is considered a key pathophysiological factor in the development of type 2 diabetes. Tumor necrosis factor-alpha (TNF-alpha) can directly contribute to insulin resistance by disrupting the insulin signalling pathway via protein-tyrosine phosphatase 1B (PTP1B) activation, especially in adipocytes. Infliximab (Remicade ® ) is a TNF-alpha-neutralizing antibody that has not been fully studied in insulin resistance. We investigated the effect of infliximab on TNF-alpha-induced insulin resistance in 3T3L1 adipocytes in vitro, and examined the possible molecular mechanisms involved. Once differentiated, adipocytes were cultured with 5 mmol L −1 2-deoxy-D-glucose-3 H and stimulated twice with 2 μmol L −1 insulin, in the presence or absence of 5 ng/mL TNF-alpha and/or 10 ng/mL infliximab. Glucose uptake was measured every 20 minutes for 2 hour, and phosphorylated forms of insulin receptor (IR), insulin receptor substrate-2 (IRS-2), protein kinase B (AKT) and PTP1B were determined by Western blotting. TNFalpha-treated adipocytes showed a significant 64% decrease in insulin-stimulated glucose uptake as compared with control cells, whereas infliximab reversed TNFalpha actions by significantly improving glucose incorporation. Although IR phosphorylation remained unaltered, TNF-alpha was able to increase PTP1B activation and decrease phosphorylation of IRS-2 and AKT. Notably, infliximab restored phosphorylation of IRS-2 and AKT by attenuating PTP1B activation. This work demonstrates for the first time that infliximab ameliorates TNF-alpha-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring the insulin signalling pathway via PTP1B inhibition. Further clinical research is needed to determine the potential benefit of using infliximab for treating insulin resistance in patients.
containing glucose transporter proteins (GLUT) into the plasma membrane that facilitates transport of glucose for cell metabolism. 1, 2 Glucose uptake via activation of the IRS-PI3K-AKT pathway is able to reduce glucose levels in the extracellular milieu, which in turn contributes to decrease hyperglycaemia. 3 In insulin resistance, activation of the insulin signalling pathway is progressively abrogated resulting in glucose intolerance, hyperglycaemia and hyperinsulinemia. 4 For this reason, insulin resistance is considered a key pathophysiological factor in the development of type 2 diabetes (T2D), 4 ,5 a chronic disease with increasing morbidity and mortality rates around the globe. 6 TNF-alpha is a cytokine with prominent actions in cell differentiation and apoptosis, inflammation, autoimmunity and recruitment of other immune cell types toward peripheral tissues. [7] [8] [9] TNF-alpha has been also shown to play a pivotal role in glucose homeostasis by promoting insulin resistance in mice and humans, especially in adipose tissue. 10, 11 In this sense, mRNA and protein levels of TNFalpha have been previously reported to elevate in visceral adipose tissue of high-fat diet (HFD)-fed mice and obese subjects that show increased insulin resistance. 12 Moreover, TNF-alpha-deficient mice are protected against insulin resistance development, 13 while also TNF-alpha directly induces insulin resistance in 3T3L1 adipocytes in vitro.
14 TNF-alpha favours insulin resistance by abrogating phosphorylation of IRS-1 and AKT in a variety of insulindependent cells including adipocytes. 15 Besides reducing IRS-1 and AKT activation, TNF-alpha can also attenuate GLUT4 expression in adipocytes, 11, 16 which demonstrates that this proinflammatory cytokine is able to disrupt the insulin signalling pathway in adipose tissue. Thus, blockage of TNF-alpha actions is now considered a matter of urgency to improve insulin action in adipose tissue of patients with insulin resistance such as T2D patients. Infliximab (Remicade   ®   ) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-alpha and prevents the interaction of TNF-alpha with TNF-alpha receptor (TNFR) 1 and TNFR2. 17 For this reason, infliximab has been used to treat a variety of autoimmune and chronic inflammatory diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis and ankylosing spondylitis. [18] [19] [20] [21] [22] [23] Interestingly, besides exerting anti-inflammatory actions, infliximab has been also shown to improve insulin resistance. In this sense, rheumatoid arthritis patients receiving infliximab show decreased values of the homeostatic model assessment of insulin resistance (HOMA-IR) as well as increase in the quantitative insulin sensitivity check index (QUICKI). 24 Similarly, non-diabetic patients with ankylosing spondylitis also exhibit reduced HOMA-IR and increased QUICKI after 2 hour of receiving an intravenous infliximab infusion. 25 However, despite the clinical evidence, there are no studies exploring the effect of infliximab on TNF-alpha-induced insulin resistance in target organs of insulin such as adipose tissue. Here, we investigated the effect of infliximab on TNFalpha-induced insulin resistance in 3T3L1 adipocytes in vitro and examined the possible molecular mechanisms involved.
| MATERIAL AND METHODS

| 3T3L1 cell line differentiation
The murine 3T3L1 cell line (ATCC ® , USA) was propagated in Dulbecco's Modified Eagle Medium (DMEM)-High Glucose (Thermo Fisher-Scientific, USA) containing 10% foetal bovine serum (FBS) and 50 μg/mL gentamicin (Sigma-Aldrich, USA) for 4 days at 37°C in humidified 5% CO 2 atmosphere, using 6-well cell-culture plates (Costar, USA) at a density of 50 × 10 3 cells per well. Once fibroblasts reached about 80% confluence, they were differentiated into adipocytes using DMEM supplemented with 10% FBS, 50 μg/mL gentamicin,
IBMX and 1 μmol L −1 insulin (Sigma-Aldrich, USA). Culture media were replaced every other day for 6 days. Mature adipocytes were seen after 10 days on the in vitro culture conditions described above.
| Glucose uptake assay
For glucose uptake assay, 3T3L1 mature adipocytes were in vitro cultured in DMEM containing 10% FBS, 50 μg/mL gentamicin and 5 mmol L −1 2-deoxy-D-glucose-3 H (SigmaAldrich, USA) for 2 hour at 37°C in humidified 5% CO 2 atmosphere, using 6-well cell-culture plates at a density of 30 × 10 4 cells per well. Adipocytes were stimulated twice at zero and 60 minutes with 2 μmol L −1 insulin. In the infliximab-treated group, adipocytes were stimulated with 10 ng/mL infliximab (Remicade ® , Janssen Biotech, USA)
at the beginning of the 2-hour in vitro assay. In the TNFalpha-treated group, adipocytes were stimulated with 5 ng/ mL murine TNF-alpha (Peprotech,Mexico) at the beginning of the 2-hour in vitro assay. In the infliximab+TNF-alphatreated adipocyte group, 10 ng/mL infliximab was added at the beginning of the 2-hour in vitro assay, whereas 5 ng/mL murine TNF-alpha was added five minutes later. Control cells received neither infliximab nor TNF-alpha stimulation. All cultured 3T3L1 adipocytes were collected every 20 minutes for 2 hour for measuring glucose uptake in counts per minute (cpm), using a liquid scintillation counter (Beckman-Coulter, USA).
| Western blot for pIR, pIRS-2, pAKT and pPTP1B
Two hours after having been incubated with or without TNFalpha and/or infliximab, 3T3L1 adipocytes were collected and disrupted in protein extraction buffer containing 500 mmol L Protein bands for pIR, pIRS-2, pAKT and pPTP1B were visualized using the peroxidase-diaminobenzidine reaction (Sigma-Aldrich, Mexico) and quantified by optical density (OD) analysis using beta-Actin as control.
| Statistical analysis
The Shapiro-Wilk test was performed to estimate normality in data distribution and then proceed to perform one-way ANOVA followed by a post-hoc Tukey test. Data represent at least five independent experiments and are expressed as media ± SD. Statistical analysis was performed using the GraphPad Prism 6.01 software. Areas under the curve (AUC) were calculated using R statistics and expressed as arbitrary units (a.u). Differences were considered significant when P < 0.05.
| RESULTS
After 40 minutes of having been in vitro stimulated with insulin, TNF-alpha-treated 3T3L1 adipocytes started to show a significant decrease in glucose uptake with respect to control untreated cells ( Figure 1A ). Infliximab exhibited no deleterious effects on glucose incorporation when added alone but clearly blocked TNF-alpha actions by improving glucose uptake in 3T3L1 cells in vitro ( Figure 1A ). At the end of the in vitro culture, 3T3L1 adipocytes treated with TNF-alpha showed a significant 2.6-fold reduction in glucose incorporation as compared to control cells (P < 0.0001). In contrast, adipose cells stimulated with infliximab and TNF-alpha exhibited a 2-fold increase in glucose uptake with respect to adipocytes only treated with TNF-alpha (P < 0.0001), H as well as infliximab and/or TNF-alpha for 2 hours. Control adipocytes received neither infliximab nor TNF-alpha stimulation. (A) After 40 minutes, TNF-alpha (dotted grey line with solid squares) significantly decreased glucose uptake in 3T3L1 adipocytes as compared to control (black line with solid circles) and infliximab-treated adipocytes (dotted grey line with solid triangles). In contrast, infliximab restored cellular glucose incorporation by inhibiting TNF-alpha (dotted black line with hollow rhombus). Asterisks (*) indicate significant differences with respect to control untreated cells. (B) Glucose uptake kinetics in all groups was quantified as area under the curve (AUC). Overall, TNF-alpha induced 64% decrease in the AUC of glucose uptake as compared with control and infliximab-treated adipocytes. On the contrary, infliximab partially blocked TNF-alpha actions by increasing 50% the AUC of glucose uptake in 3T3L1 adipocytes. Asterisks (*) indicate significant differences among groups. Data are expressed as media ± SD. Significant differences were estimated by means of performing one-way ANOVA followed by a post-hoc Tukey test. Differences were considered significant when P < 0.05 and can be seen as asterisks (*) on the figure. TNF-alpha, tumor necrosis factor-alpha; cpm, counts per minute; a.u., arbitrary units although glucose incorporation values were 0.15-fold lower than those found in control cells (P = 0.0002) ( Figure 1A) . Glucose uptake kinetics in 3T3L1 adipocytes was also analyzed as area under the curve (AUC) and can be seen in Figure 1B . Overall, TNF-alpha-treated 3T3L1 adipocytes showed a significant 64% decrease in the AUC of glucose uptake as compared with control cells (P < 0.0001) (Figure 1B) . On the contrary, infliximab did not alter the AUC of glucose incorporation when added alone but partially reverted TNF-alpha actions by increasing 50% the AUC of glucose uptake in these adipose cells (P < 0.0001) (Figure 1B) . Although use of infliximab significantly reversed the effect of TNF-alpha on 3T3L1 adipocytes in vitro, the AUC of glucose incorporation was 15% lower than that found in control cells (P < 0.001) ( Figure 1B) .
Neither TNF-alpha nor infliximab, alone or combined, altered the phosphorylation pattern of pIR in 3T3L1 adipocytes when compared to untreated cells (Figure 2A,  B) . On the contrary, pIRS-2 was significantly decreased by 3.25-fold in 3T3L1 adipocytes treated with TNF-alpha as compared to untreated cells (P < 0.0001) (Figure 2A,  C) . Infliximab showed no effect on pIRS-2 when added alone but significantly reverted TNF-alpha actions by restoring phosphorylation of pIRS-2 at similar levels than those found in control cells (P < 0.0001) (Figure 2A, C) . When in vitro treated with TNF-alpha, 3T3L1 adipocytes showed a significant 2-fold decrease in pAKT as compared to untreated cells (P < 0.0001) (Figure 2A, D) . On the other hand, infliximab had no effect on pAKT when added alone but partially reestablished phosphorylation of this protein in TNF-alpha-treated 3T3L1 adipocytes (P = 0.0021); however, AKT phosphorylation levels remained nether in comparison to control cells (Figure 2A and D) (P = 0.0034). The beta-Actin was used as control for optical density (OD) analysis. (B) According to OD analysis, neither TNF-alpha nor infliximab, alone or combined, altered pIR in 3T3L1 adipocytes. (C) TNF-alpha induced 65% decrease in pIRS-2 as compared with control and infliximab-treated adipocytes. On the contrary, infliximab blocked TNF-alpha actions by restoring phosphorylation of IRS-2 in 3T3L1 adipocytes. (D) TNF-alpha induced 50% decrease in pAKT as compared with control and infliximab-treated adipocytes. On the other hand, infliximab blocked TNF-alpha actions by partially restoring phosphorylation of AKT in 3T3L1 adipocytes. Asterisks (*) indicate significant differences among groups. Data are expressed as media ± SD. Significant differences were estimated by means of performing one-way ANOVA followed by a post-hoc Tukey test. Differences were considered significant when P < 0.05. TNF-alpha, tumor necrosis factor-alpha; pIR, phosphorylated form of insulin receptor; pIRS-2, phosphorylated form of insulin receptor substrate-2; pAKT, phosphorylated form of protein kinase B; OD, optical density
The effects of TNF-alpha and infliximab on pPTP1B can be seen in the representative Western blotting shown in Figure 3A . TNF-alpha-treated 3T3L1 adipocytes exhibited a significant 4-fold increase in pPTP1B as compared to untreated cells (P = 0.0055) ( Figure 1B) . On the contrary, infliximab showed no effect on pPTP1B when added alone but revoked TNF-alpha actions by partially reducing phosphorylation of PTP1B in 3T3L1 adipocytes (P = 0.0372) ( Figure 3B ).
| DISCUSSION
TNF-alpha has been consistently shown to play a causal role in the development of insulin resistance in adipose tissue of HFD-fed mice and humans with obesity. For instance, T2D patients carrying the TNF-alpha 308 G/A polymorphism that has been associated with increased TNF-alpha levels, show higher values of the homeostatic model assessment of insulin resistance (HOMA-IR) than patients with the G/G wild genotype. 26 For this reason, numerous studies are now focused on finding novel therapeutic agents with the ability to abrogate the effects of TNF-alpha on insulin sensitivity, although results are still controversial. In this regard, Sprague-Dawley rats treated with goat anti-murine TNF-alpha IgG antibody showed improvement in insulin-mediated glucose transport in skeletal muscle. 27 In contrast, blockage of TNF-alpha using the recombinant-engineered human TNF-alpha-neutralizing antibody CDP571 did not show improvement in insulin sensitivity of patients with T2D. 28 Our study shows that neutralization of TNF-alpha improves glucose uptake by reversing insulin resistance and provides solid evidence regarding the use of therapeutic agents against TNF-alpha for improving insulin sensitivity in adipose cells. However, these results should be considered with caution as they reflect only the behaviour of an adipocyte cell line on in vitro culture conditions. Infliximab is a medication used to treat patients with autoimmune and chronic inflammatory diseases. [18] [19] [20] [21] [22] Notably, besides improving joint pain, swelling and inflammation, infliximab also reduces the levels of serum insulin, fasting glucose and insulin resistance in patients with ankylosing spondylitis and rheumatoid arthritis. 29, 30 It has been also reported that obese people show improvement in insulin resistance when treated with 5 mg/kg infliximab every 2 months, including a T2D patient who did not longer require insulin administration about 5 months after infliximab therapy. 31 Concurring with previous evidence, our data reveal that infliximab directly reverses insulin resistance and restores glucose homeostasis in adipose cells, even under proinflammatory conditions such as those promoted by TNF-alpha.
Another phenomenon captured in our study involves the possible molecular mechanism by which infliximab exerts its beneficial effects on TNF-alpha-induced insulin resistance in 3T3L1 adipocytes in vitro. Our data show that TNF-alpha is not able to impair insulin-mediated IR phosphorylation, a finding that has been previously reported in mice and rats. 14, 32, 33 Thus, it is reasonable to consider that TNF-alpha may promote adipocyte insulin resistance by inducing downstream activation of PTP1B. PTP1B is a negative regulator of the insulin signalling pathway with the ability to dephosphorylate tyrosine residues in numerous activated tyrosine kinase proteins including the IRS protein family. 33, 34 A previous work reported that mice However, infliximab blocked TNF-alpha actions by decreasing PTP1B activation in 3T3L1 adipocytes. Asterisks (*) indicate significant differences among groups. Data are expressed as media ± standard deviation. Significant differences were estimated by means of performing one-way ANOVA followed by a post-hoc Tukey test. Differences were considered significant when P < 0.05. TNF-alpha, tumor necrosis factor-alpha; pPTP1B, phosphorylated form of proteintyrosine phosphatase 1B; OD, optical density lacking PTP1B expression (PTP1B −/− ) show enhanced insulin sensitivity and normal body weight, even after having been fed a HFD. 35 Notably, re-expression of PTP1B in the liver of PTP1B −/− mice attenuated whole-body insulin sensitivity and IRS-2 activation in hepatocytes. 35 A similar study showed that PTP1B activity abrogates phosphorylation of IRS-1 in skeletal muscle cells that results in decreased insulin sensitivity and altered glucose homeostasis. 36 Our data expand on this body of work by revealing for the first time that TNF-alpha-induced PTP1B activation can directly decrease phosphorylation of IRS-2 in adipose cells, which in turn might lead to AKT inhibition and increased insulin resistance. Furthermore, our results also demonstrate that infliximab is able to reverse PTP1B activation, which (a) confirms the causative role of TNF-alpha in insulin resistance and (b) might explain the improvement of IRS-2 phosphorylation and glucose uptake in adipocytes exposed to a proinflammatory milieu ( Figure 4 ). PTP1B has now emerged as a key molecule in mediating TNF-alpha-induced insulin resistance in insulindependent cells as is the case of skeletal muscle cells and adipocytes. For this reason, a growing number of studies have examined the effect of PTP1B inhibitors on insulin resistance. In this sense, Yi-ming Ma and coworkers previously showed that CCF06240, a PTP1B inhibitor, restores insulin sensitivity in HFD-fed mice and promotes phosphorylation of IRS-1 in HepG2 cells in vitro. 37 Similarly, a recent study reported a decrease in blood glucose and insulin resistance in ob/ob mice receiving Fudan-YueyangGanoderma-lucidum (FYGL), a proteoglycan with the ability to inhibit PTP1B. 38 Interestingly, FYGL was also shown to improve insulin-stimulated glucose uptake and activation of IRS-1, PI3K and AKT by blocking PTP1B activation in rat myoblast L6 cells. 38 Consistent with previous evidence, we found that infliximab also acts as PTP1B inhibitor by exerting the ability to improve insulin signalling pathway and consequently glucose homeostasis in 3T3L1 adipocytes exposed to TNF-alpha in vitro.
Little is known yet about the activity of PTP1B in other tissues different from adipose tissue. In this sense, F I G U R E 4 Possible molecular mechanism involved in mediating the effect of infliximab on TNF-alpha-induced insulin resistance in adipocytes in vitro. In TNF-alpha-induced insulin resistance (left panel), TNF-alpha binds to TNFR found on the cell surface of adipocytes, which in turn triggers PTP1B activation. Downstream, PTP1B is able to dephosphorylate IRS-2 that in turn leads to AKT arrest, even though insulin is continually binding to IR. Alternatively, AKT phosphorylation may be directly inhibited by PTP1B; however, there are not yet solid evidence supporting this notion. As a consequence of IRS-2 and AKT attenuation, GLUT4 translocation into the plasma membrane is arrested that in turn impedes the intracellular transport of glucose and leads to hyperglycaemia. On the contrary (right panel), infliximab specifically binds to TNF-alpha and neutralizes the interaction of TNF-alpha with TNFR that results in PTP1B attenuation. In consequence, IRS-2 and AKT are normally phosphorylated in response to insulin, which facilitates membrane translocation of GLUT4 and promotes glucose homeostasis, even when TNF-alpha levels are elevated. TNF-alpha, tumor necrosis factor-alpha; TNFR, tumor necrosis factor-alpha receptor; PTP1B, proteintyrosine phosphatase 1B; IR, insulin receptor; IRS-2, insulin receptor substrate-2; AKT, protein kinase B; GLUT4, glucose transporter protein 4 liver-specific PTP1B −/− mice show improved glucose homeostasis and lipid metabolism, accompanied by reduction in HFD-induced endoplasmic reticulum stress. 39 Interestingly, aging has been shown to increase PTP1B expression and insulin resistance in liver of rats, a phenomenon that can be reversed by workout. 40 It has been also shown that PTP1B contributes to hypothalamic inflammation and leptin resistance in rodents fed a HFD. 41 As a matter of fact, PTP1B −/− mice exhibit decreased TNF-alpha expression, accompanied by increased interleukin-10 mRNA levels in the hypothalamus, even under HFD-feeding. 42 Notably, TNF-alpha has been shown to increase PTP1B expression in hypothalamic organotypic cultures in a dose and time-dependent fashion. 43 Nevertheless, despite PTP1B has been consistently shown to mediate insulin and leptin resistance in response to proinflammatory signals including endoplasmic reticulum stress, aging and TNF-alpha, there is still scant evidence regarding the benefit of using PTP1B and TNF-alpha-specific inhibitors. In this sense, this work brings to light the potential impact of using infliximab as a PTP1B inhibitor for ameliorating TNF-alpha-induced insulin resistance in adipose tissue. For this reason, we encourage exploring the possible effect of infliximab on other signaling cascades stimulated by TNF-alpha that may also disrupt insulin-dependent glucose uptake in adipocytes in vitro and in vivo, such as those depending on ceramides and extracellular-signal-regulated kinases (ERK). The implications for understanding the mechanisms through which infliximab improves TNF-alphainduced insulin resistance are profound, and the idea that further knowledge of these pathways might allow prediction of susceptibility to type 2 diabetes adds a compelling degree of urgency to further study.
In conclusion, this work demonstrates for the first time that infliximab ameliorates TNF-alpha-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring phosphorylation of key mediators of the insulin signaling pathway such as IRS-2 and AKT via PTP1B inhibition that in consequence improves insulin-dependent glucose uptake in these adipose cells (Figure 4 ). 
ACKNOWLEDGMENT
